KDR and neoplasm: Lenvatinib, a multi-target tyrosine kinase inhibitor, selectively inhibits vascular endothelial growth factor receptor (VEGFR) 1–3 and modulates the VEGF-VEGFR pathway to enhance anti-tumor immunity [30, 31].